<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886232</url>
  </required_header>
  <id_info>
    <org_study_id>M930061001</org_study_id>
    <nct_id>NCT04886232</nct_id>
  </id_info>
  <brief_title>A Prospective, Multicenter, Randomized, Comparator-controlled, Evaluator-blinded Study to Evaluate the Safety and Effectiveness of VP1 Lido US for Volume Augmentation of the Cheek</brief_title>
  <acronym>BCheek</acronym>
  <official_title>A Prospective, Multicenter, Randomized, Comparator-controlled, Evaluator-blinded Study to Evaluate the Safety and Effectiveness of VP1 Lido US for Volume Augmentation of the Cheek</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to demonstrate non-inferiority of VP1 Lido US versus an&#xD;
      approved hyaluronic acid dermal filler following deep (subdermal and/or supraperiosteal)&#xD;
      injection of the cheek for volume augmentation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Week 12 on the Merz Cheeks Fullness Assessment Scale (MCFAS)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>The MCFAS is a 5-point ordinal rating</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 on the MCFAS by injection type (cannula, needle)</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response rate where response is defined as a ≥ 1-point improvement on both cheeks when comparing the change from baseline to Week 12</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FACE-Q satisfaction with cheeks for treated subjects at baseline and Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) scores for treated subjects at Week 12, as completed by the treating investigator</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAIS scores for treated subjects at Week 12, as completed by the subject</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rates at Week 12, according to the MCFAS, as assessed by three blinded board-certified Independent Panel Reviewers (IPRs) using subject photographs</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of related serious or delayed onset adverse events (&gt;21 days after treatment) following the first treatment including touch-up until Week 48</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cheek Volume Augmentation</condition>
  <arm_group>
    <arm_group_label>VP1 Lido US - NC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection to the left cheek via needle and to the right cheek via canula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VP1 Lido US - CN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection to the left cheek via canula and to the right cheek via needle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane Lyft Lidocaine - NC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection to the left cheek via needle and to the right cheek via canula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane Lyft Lidocaine - CN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection to the left cheek via canula and to the right cheek via needle</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VP1 Lido US</intervention_name>
    <description>Hyaluronic acid dermal filler containing lidocaine</description>
    <arm_group_label>VP1 Lido US - CN</arm_group_label>
    <arm_group_label>VP1 Lido US - NC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane Lyft Lidocaine</intervention_name>
    <description>Hyaluronic acid dermal filler containing lidocaine</description>
    <arm_group_label>Restylane Lyft Lidocaine - CN</arm_group_label>
    <arm_group_label>Restylane Lyft Lidocaine - NC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a symmetrical rating of 2 (moderate) or 3 (severe) for right and left cheek on the&#xD;
             Merz Cheeks Fullness Assessment Scale (MCFAS)&#xD;
&#xD;
          -  Desires cheek augmentation to correct volume deficit in the midface and is willing to&#xD;
             receive sufficient volume to achieve at least a 1-point improvement on the MCFAS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Skin or fat atrophy in the midfacial region other than that related to age.&#xD;
&#xD;
          -  Subjects with body mass index of &lt;18.5 or ≥30&#xD;
&#xD;
          -  Acute inflammatory process or active infection at the injection site (e.g., acne,&#xD;
             eczema, streptococcus infections), or history of chronic or recurrent infection or&#xD;
             inflammation with the potential to interfere with the study results or increase the&#xD;
             risk of AEs.&#xD;
&#xD;
          -  Prior surgery, including midfacial plastic surgery, or has a permanent implant or&#xD;
             graft in the midfacial region that could interfere with effectiveness assessments.&#xD;
&#xD;
          -  Received midfacial region treatments with porcine-based collagen fillers or with&#xD;
             RADIESSE® or with volumizing hyaluronic acid fillers such as but not limited to&#xD;
             Juvéderm® Voluma, Restylane® Lyft within the past 24 months and/or with other HA&#xD;
             fillers or mesotherapy within the past 12 months or plans to receive such treatments&#xD;
             during participation in the study.&#xD;
&#xD;
          -  Received facial dermal therapies (i.e., facial ablative or fractional laser,&#xD;
             dermabrasion, chemical peels, non-invasive skin-tightening [e.g., Ultherapy®,&#xD;
             Thermage®] and surgical procedures) in the midfacial region within the past 12 months&#xD;
             or plans to receive them in the facial region during participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merz Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Pharmaceuticals GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Public Disclosure Manager</last_name>
    <phone>+49 69 1503 0</phone>
    <email>Aesthetic.Trials@merz.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hautmedizin Bad Soden, Merz Investigational Site #0490189</name>
      <address>
        <city>Bad Soden am Taunus</city>
        <zip>65812</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rosenparkklinik, Merz Investigational Site #0490099</name>
      <address>
        <city>Darmstadt</city>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis für Hautkrankheiten, Merz Investigational Site #0490375</name>
      <address>
        <city>Drensteinfurt</city>
        <zip>48317</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatologic Private Practive, Merz Investigational Site #0490381</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universität Hamburg, Merz Investigational Site #0490095</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatologic Private Practice, Merz Investigational Site #0490345</name>
      <address>
        <city>Hamburg</city>
        <zip>22609</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Private Clinic, Merz Investigational Site #0490284</name>
      <address>
        <city>Mannheim</city>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Privatpraxis für Dermatologie und Ästhetik, Merz Investigational Site #0490371</name>
      <address>
        <city>München</city>
        <zip>80539</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haut- und Lasercentrum Potsdam, Merz Investigational Site #0490362</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centroderm GmbH, Merz Investigational Site #0490367</name>
      <address>
        <city>Wuppertal</city>
        <zip>42287</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

